The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial

Bibliographic Information
Authors: Mohamed A.A.; Halim A.A.; Mohamed S.; Mahmoud S.M.; Bahgat Eldemiry E.M.; Mohamed R.S.; Shaheen M.M.; Naguib G.G.; Muharram N.M.; Khalil M.G.; Saed S.; Ibrahim R.; Salah Seif A.; Kamal N.; Nasraldin K.; Abdelrahman A.E.; El Borolossy R.
Journal: Frontiers in Pharmacology
Publisher: Frontiers Media S.A.
Publication Date: 14 March 2023
Volume / Issue: Volume 14
Article No.: 1149967
ISSN: 16639812
DOI: 10.3389/fphar.2023.1149967
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Mohamed A.A., Department of Biochemistry and Molecular Biology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; Halim A.A., Tropical Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; Mohamed S., Tropical Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; Mahmoud S.M., Tropical Medicine Department, El Sahel Teaching Hospital, Cairo, Egypt; Bahgat Eldemiry E.M., Fellow of Clinical Pharmacology, Faculty of Pharmacy, Cairo University Hospitals, Cairo, Egypt; Mohamed R.S., Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Shaheen M.M., Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Naguib G.G., Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Muharram N.M., Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Menoufia, Egypt; Khalil M.G., Pharmacology and Toxicology Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt; Saed S., Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Ibrahim R., Clinical and Chemical Pathology Department, Nutrition Institute, Cairo, Egypt; Salah Seif A., Tropical Medicine Hepatology and Gastroenterology Department, Shebeen El-Kom Teaching Hospital, Menoufia, Egypt; Kamal N., Clinical Pathology Department, Theodor Bilharz Research Institute (TBRI), Ministry of Scientific Research and Higher Education, Gulf Medical University (GMU), Cairo, Egypt; Nasraldin K., Faculty of Biotechnology, Modern Science and Arts University, Cairo, Egypt; Abdelrahman A.E., Diagnostic and Intervention Radiology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; El Borolossy R., Department of Clinical Pharmacy, Faculty of Pharmacy Ain Shams University, Cairo, Egypt
Abstract
Background and Aim: Non-alcoholic fatty liver (NAFLD) is one of the most common progressive metabolic disorders worldwide. There are increasing scientific interests nowadays for the association between vitamin D status and Non-alcoholic fatty liver. Earlier studies have revealed that vitamin D deficiency is highly prevalent in Non-alcoholic fatty liver patients that contributes to poor outcomes. Hence, the present study aimed to assess the efficacy and safety of oral cholecalciferol on Non-alcoholic fatty liver patients. Subjects and Methods: This study was conducted on 140 patients that were randomized either to group 1 that received the standard conventional therapy in addition to placebo or group 2 that received the standard conventional therapy in addition to cholecalciferol during the 4 months study period. Results: At the end of the study group 2 revealed significant decrease (p < 0.05) in the mean serum level of TG, LDL-C, TC, hsCRP as compared to their baseline results and group 1 results. Additionally, a significant improvement in the serum levels of ALT (p = 0.001) was seen in group 2 at the end of the study when compared to group 1. Whereas group 1 did not show any change in these parameters when compared to group 2 and their baseline results. Conclusion: Cholecalciferol was shown to have beneficial effects on serum ALT levels, hsCRP levels and lipid profile of NAFLD patients. Clinical Trial Registration: https://prsinfo.clinicaltrials.gov/prs-users-guide.html, identifier NCT05613192. Copyright © 2023 Mohamed, Halim, Mohamed, Mahmoud, Bahgat Eldemiry, Mohamed, Shaheen, Naguib, Muharram, Khalil, Saed, Ibrahim, Salah Seif, Kamal, Nasraldin, Abdelrahman and El Borolossy.
Keywords
Cholecalciferol; hsCRP; lipid profile; non-alcoholic fatty liver; Steatosis; alanine aminotransferase; C reactive protein; cholesterol; colecalciferol; low density lipoprotein; placebo; triacylglycerol; adult; alanine aminotransferase level; Article; controlled study; drug efficacy; drug safety; echography; female; glycemic control; human; insulin resistance; lipid fingerprinting; loading drug dose; low density lipoprotein cholesterol level; major clinical study; male; metabolic fingerprinting; nonalcoholic fatty liver; protein expression level; randomized controlled trial; single drug dose; total cholesterol level; triacylglycerol blood level
Citation Information
Scopus Citations: 7
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
